FDA Expands Anktiva to Papillary-Only Bladder Cancer

FDA has expanded Anktiva's approval to cover a bladder-cancer population that, by ImmunityBio's own estimate, makes up roughly 85 percent of non-muscle invasive bladder cancer patients — and it did so without requiring the company to run a new confirmatory trial. The 14 October 2026 decision extends the immunotherapy's label from carcinoma-in-situ disease to BCG-unresponsive, high-grade, papillary-only tumors, resting on a scientific-extrapolation argument rather than fresh efficacy data.

What changed, and what the evidence actually is

Anktiva's original 2024 approval was itself notable: a 62% complete response rate from a 77-patient, single-arm trial, with no internal control arm, cleared the bar for a serious unmet need — BCG-unresponsive CIS, a population with few good options short of cystectomy. The October 2026 expansion stretches that same evidentiary base further. High-grade papillary tumors and carcinoma in situ are histologically distinct — papillary disease grows in finger-like projections into the bladder lumen, while CIS is flat and confined to the mucosal surface — but FDA's own public reasoning, as reported by multiple outlets covering the decision, treated them as biologically related enough that efficacy demonstrated in one justifies approval in the other, given that the two patterns frequently coexist in the same bladder and are treated with the same immunotherapeutic mechanism.

Why extrapolation instead of a new trial

A randomized trial in BCG-unresponsive, papillary-only NMIBC would have been expensive and slow to enroll — this is already a BCG-unresponsive population, meaning patients have exhausted first-line therapy and a conventional comparator arm raises its own ethical and recruitment difficulties. FDA's willingness to rely on extrapolation here reflects a broader pattern in oncology-drug and biologics review: where a sponsor can build a sufficiently coherent scientific case that two disease presentations share mechanism and expected treatment effect, the agency has shown it will accept cross-subtype efficacy bridging in place of a dedicated trial. That calculus does not apply automatically — FDA case reviews are product- and disease-specific, and the agency has rejected extrapolation arguments it judged too speculative in other programs. What makes this one worth tracking is the combination of a rapid timeline (nearly three months early) and clear public reasoning about why the bridge was accepted here, which gives other sponsors a concrete reference point rather than an abstract policy statement.

The regulatory path was not smooth

Trade coverage of the expansion describes a bumpy run-up: an earlier refusal-to-file on part of ImmunityBio's submission history with this product, before the company resubmitted on a path that ultimately succeeded well ahead of its own target date. That history matters for how sponsors should read this result — it is not evidence that extrapolation arguments sail through on a first pass, but that a well-constructed scientific rationale, resubmitted correctly, can still land faster than the standard PDUFA clock once FDA is persuaded.

• Sponsors weighing a subtype-extrapolation strategy for a supplemental application should study the biological-relatedness argument FDA accepted here — shared mechanism, frequent coexistence of the two presentations in the same patient — as a template for what a persuasive case looks like.
• A refusal-to-file is not necessarily fatal to an eventual extrapolation-based approval, provided the resubmission addresses whatever triggered the original filing rejection.
• This is a BLA precedent, not a 510(k) or device one — the extrapolation logic here concerns clinical efficacy bridging across histologic subtypes of the same cancer, a distinct question from device-side predicate or substantial-equivalence arguments.

Frequently asked questions

What did FDA approve on 14 October 2026?

An expanded indication for Anktiva (nogapendekin alfa inbakicept-pmln), ImmunityBio's IL-15 superagonist immunotherapy, used with BCG. The label now covers adults with BCG-unresponsive, high-grade, non-muscle invasive bladder cancer (NMIBC) that is papillary-only, in addition to the carcinoma-in-situ (CIS) population it already covered.

What was Anktiva approved for originally?

FDA approved Anktiva on 22 April 2024, with BCG, for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors. The approval rested on QUILT-3.032, a single-arm, 77-patient trial that reported a 62% complete response rate in the CIS cohort.

Did ImmunityBio run a new trial for papillary-only disease?

No. FDA granted the expansion without a new pivotal trial, reasoning that high-grade papillary tumors and CIS are both aggressive forms of urothelial carcinoma that frequently coexist in the same patient, and that the CIS efficacy data could be extrapolated to the papillary-only population. The decision came nearly three months ahead of the 6 January 2027 target action date.

Why does this matter beyond bladder cancer?

It is a concrete, recent example of FDA accepting scientific-rationale extrapolation across histologic subtypes of the same disease in place of a dedicated randomized trial for a supplemental indication — a precedent regulatory affairs teams building bridging strategies for other label expansions will want to study closely.